Lance Willsey Buys 50,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) Director Lance Willsey bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $4.75 per share, with a total value of $237,500.00. Following the purchase, the director owned 1,291,780 shares in the company, valued at $6,135,955. This trade represents a 4.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

FocalTherics Stock Down 2.3%

FOCL opened at $4.26 on Wednesday. The firm has a market cap of $159.66 million, a price-to-earnings ratio of -4.14 and a beta of -0.04. The firm has a 50 day simple moving average of $5.38. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. FocalTherics has a 12-month low of $1.30 and a 12-month high of $6.40.

FocalTherics (NASDAQ:FOCL) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million during the quarter. As a group, analysts anticipate that FocalTherics will post -0.78 earnings per share for the current year.

FocalTherics News Roundup

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

Institutional Investors Weigh In On FocalTherics

A number of institutional investors have recently bought and sold shares of the business. Flax Pond Capital LLC bought a new stake in FocalTherics in the fourth quarter valued at $2,623,000. Leonteq Securities AG bought a new position in shares of FocalTherics during the fourth quarter valued at $313,000. Rock Springs Capital Management LP lifted its holdings in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after acquiring an additional 91,500 shares during the period. Kovack Advisors Inc. acquired a new stake in shares of FocalTherics in the 4th quarter valued at $53,000. Finally, Lido Advisors LLC acquired a new stake in shares of FocalTherics in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

Wall Street Analyst Weigh In

FOCL has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday. Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. Finally, Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, FocalTherics has an average rating of “Hold” and a consensus target price of $7.75.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.